The top after-market NASDAQ stock market gainers are: Orthovita, Allos Therapeutics, ICAgen, Biodel, and eBay. The top after-market NASDAQ stock market losers are: MannKind, F5 Networks, Westell Technologies, Internap Network Services, and Riverbed Technology.
Shares of Orthovita Inc. (VITA) advanced 8.51 percent to $2.55 in the after-market trading.
Allos Therapeutics, Inc. (ALTH) stock rose 5.66 percent to $4.11 in the after-hours trading. The company said the Journal of Clinical Oncology has published data from its pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The study results show an overall response rate of 29 percent observed in patients treated with FOLOTYN.
Shares of ICAgen Inc. (ICGN) gained 5.44 percent to $3.10 in the after-market session.
Biodel Inc. (BIOD) stock increased 5.26 percent to $2.40 in the after-hours session.
Shares of eBay Inc. (EBAY) rose 3.02 percent to $29.98 in the after-market trading, following its better-than-expected fourth quarter earnings. Adjusted profit was $684 million or 52 cents a share, up from $586 million or 44 cents a share last year. Revenue rose 5 percent to $2.5 billion. Analysts had expected profit of 47 cents a share on revenue of $2.49 billion.
eBay expects first quarter adjusted earnings of 44 cents to 46 cents a share and revenue of $2.4 billion to $2.5 billion, while analysts project profit of 45 cents a share on revenue of $2.43 billion. The company anticipates full year 2011 adjusted profit of $1.90 to $1.95 a share and revenue of $10.3 billion to $10.6 billion, while Street expects profit of $1.85 a share on revenue of $10.19 billion.
MannKind Corp. (MNKD) stock lost 44.02 percent to $5.10 in the after-hours trading, as FDA has rejected its new drug application for Afrezza Inhalation Provider, a diabetic therapy. FDA asked the company to conduct two clinical trials of the inhaler, one in patients with type 1 diabetes and one in type 2 diabetes, with at least one trial including a treatment group using the MedTone inhaler for purpose of comparison.
MannKind's Afrezza is a novel, ultra rapid acting mealtime insulin therapy for the treatment of adult patients with type 1 and type 2 diabetes for the control of hyperglycemia. It is a drug-device combination product, consisting of Afrezza Inhalation Powder pre-metered into single use dose cartridges and Afrezza Inhaler.
Shares of F5 Networks, Inc. (FFIV) plunged 22.31 percent to $107.82 in the after-market trading, after its first quarter revenue and forecast for second quarter sales missed analysts expectations. Adjusted profit for first quarter was $72.7 million or 88 cents a share, up from $41.4 million or 52 cents a share last year. Revenue grew 41 percent to $268.9 million. Analysts had expected profit of 83 cents a share on revenue of $270.34 million.
F5 Networks expects second quarter adjusted earnings of 84 cents to 86 cents a share and revenue of $275 million to $280 million. Street analysts expect earnings of 85 cents a share on revenue of $280.72 million.
Westell Technologies Inc. (WSTL) stock plummeted 11.11 percent to $3.20 in the after-hours session. Profit for third quarter was $2.9 million or 4 cents a share, compared to $2.7 million or 4 cents a share last year. Revenue rose 13 percent to $48.3 million.
Shares of Internap Network Services Corp. (INAP) declined 9.91 percent to $6 in the after-market session.
Riverbed Technology, Inc. (RVBD) stock decreased 9.68 percent to $33.39 in the after-hours trading.
F5 Networks' weak sales forecast knocked down network equipment stocks on concerns that the market for managing the explosion in Internet traffic may not be growing as fast as expected, according to Reuters. Shares of Cisco Systems, Inc. (CSCO) were down 0.58 percent, while those in Riverbed fell 9.68 percent in post-market trading. Blue Coat Systems, Inc. (BCSI) slumped 7.95 percent and data center services provider Equinix Inc (EQIX) declined 2.62 percent.